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Abstract
Human African trypanosomiasis (HAT) is caused by infection due to protozoan parasites of the
Trypanosoma genus and is a major fatal disease throughout sub-Saharan Africa. After an early
hemolymphatic stage in which the peripheral tissues are infected, the parasites enter the CNS
causing a constellation of neurologic features. Although the CNS stage of HAT has been
recognized for over a century, the mechanisms generating the neuroinﬂammatory response are
complex and not well understood. Therefore a better understanding of the mechanisms utilized
by the parasites to gain access to the CNS compartment is critical to explaining the generation
of neuroinﬂammation. Contrast-enhanced MRI in a murine model of HAT has shown an early
and progressive deterioration of blood-CNS barrier function after trypanosome infection that
can be reversed following curative treatment. However, further studies are required to clarify
the molecules involved in this process. Another important determinant of brain inﬂammation is
the delicate balance of proinﬂammatory and counterinﬂammatory mediators. In mouse models
of HAT, proinﬂammatory mediators such as tumor necrosis factor (TNF)-α, interferon (IFN)-
γ, and CXCL10 have been shown to be crucial to parasite CNS invasion while administration of
interleukin (IL)-10, a counter inﬂammatory molecule, reduces the CNS parasite burden as well
as the severity of the neuroinﬂammatory response and the clinical symptoms associated with
the infection. This review focuses on information, gained from both infected human samples
and animal models of HAT, with an emphasis on parasite CNS invasion and the development of
neuroinﬂammation.
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For over a century, human African trypanosomiasis (HAT),
also known as sleeping sickness, has been associated with the
development of neuroinﬂammation.1–3 However, there is still
a signiﬁcant amount of detail that we do not fully understand
regarding the mechanisms that initiate and control the in-
ﬂammatory response that develops within the CNS as the
disease progresses. HAT is endemic in 36 sub-Saharan African
countries and results from infection due to the protozoan
parasites Trypanosoma brucei (T.b.) gambiense and T.b.
rhodesiense.4 T.b. gambiense is responsible for around 97% of
HAT cases, while T.b. rhodesiense accounts for the remaining
3% of the reported cases. The infection is spread via the bite of
the tsetse ﬂy vector, so the presence of this insect demarcates
the geographical distribution of the infection.4 Because of the
improved and sustained disease surveillance and control
measures, the incidence rate for HAT has dropped signiﬁcantly
in recent years.5 Even though the reported case numbers
continue to decline, the newly identiﬁed presence of asymp-
tomatic carriers6,7 together with sociopolitical instability8 in
many endemic regions raises concerns regarding the feasibility
of theWorldHealth Organization’s (WHO) target to eliminate
HAT as a public health problem by 2020 and interrupt its
transmission by 2030.4
HAT disease spectrum
The 2 subspecies of trypanosome are endemic in discrete
geographical regions and produce temporally distinct disease
proﬁles. T.b. gambiense is found in West and Central Africa
and follows a chronic progressive course that can persist for
months to years before entering the ﬁnal stages whereas the
T.b. rhodesiense variant is present in East and Southern Africa
and results in a more acute disease that progresses rapidly with
an average duration of only weeks to months.4,9,10 The geo-
graphical distinction between these 2 disease forms is be-
coming less pronounced as the topographical range of the
diﬀerent subspecies is gradually moving closer and could soon
overlap due to the movement of both people and domestic
cattle, which act as reservoir hosts for T.b. rhodesiense.11 T.b.
gambiense and T.b. rhodesiense are indistinguishable by mi-
croscopy and can only be diﬀerentiated using molecular
methods that are not commonly available in the African ﬁeld.
Therefore, if the range of these 2 parasites were to merge, this
would confound current diagnostic approaches and could lead
to administration of inappropriate chemotherapy.12
The clinical progression of HAT has been described in detail
elsewhere.4,5,9,10 Brieﬂy, after the tsetse bite, the trypano-
somes proliferate at the wound site, which can result in the
formation of a nonsuppurative but painful, indurated lesion
known as a trypanosomal chancre.4 HAT is traditionally
described as developing through 2 stages; the early or
hemolymphatic stage where the trypanosomes spread from
the initial bite site and multiply in the blood, lymphatics, and
peripheral tissues, and the late or encephalitic stage where
the parasites migrate into the CNS, producing a range of
neurologic manifestations.4,9 For many years, the infection
was considered fatal if untreated; however, there is growing
evidence that some patients aﬀected by T.b. gambiense re-
main asymptomatic and may self-cure.7
Clinical signs suggestive of neurologic involvement such as
the presence of an altered gait, incontinence, tremors, cra-
nial nerve palsy, or a reduced Glasgow Coma Scale have
been recorded during early stage infections in human
patients,13 indicating an apparent disparity between para-
sitological disease progression and the evolution of neuro-
logic signs of infection. The transition from hemolymphatic
to encephalitic stage is therefore insidious with no clear
clinical indication to distinguish between the 2 disease
stages.
Diagnosis and disease staging
Although clinical signs are suggestive of trypanosome in-
fection, they cannot be considered as diagnostic of the disease.
Many of these symptoms are found in infections such as
malaria, HIV, and tuberculosis that coexist in the same geo-
graphical areas as HAT.10,14 Consequently, diagnosis is gen-
erally a multistepped process, relying on both clinical
presentation and laboratory testing to identify the parasites
through direct detection or serologic approaches.4
Once HAT is conﬁrmed, accurate disease staging is of vital
importance in directing the appropriate chemotherapy be-
cause current therapy for late (encephalitic) stage disease is
more toxic than that of early stage disease. WHO guidelines
classify patients with more than 5 white blood cells
(WBCs)/μL and/or trypanosomes in their CSF as in the
encephalitic stage.4 This CSF WBC criterion, however, is
not universally accepted5,9 and there are no reliable bio-
markers to distinguish between the 2 disease stages. Several
molecules have been trialed with varying levels of success
(table).15–21 Research in this area is ongoing, but the cur-
rent lack of an accurate method to provide a reliable com-
parator means that researchers must depend on
the debatable WHO guidelines making this task more
challenging.22,23
Glossary
BBB = blood-brain barrier; BCSFB = blood-CSF barrier; HAT = human African trypanosomiasis; HBMEC = human brain
microvascular endothelial cell; MMP = matrix metalloproteinases; PTRE = post-treatment reactive encephalopathy; TEER =
transendothelial electrical resistance; TLR = Toll-like receptor; WBC = white blood cell.
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Chemotherapy
Treatment of HAT is complex because of a lack of safe drugs
that are eﬀective against both stages and variants of the dis-
ease. Pentamidine and suramin are used to treat stage 1 T.b.
gambiense and T.b. rhodesiense infections, respectively. When
the disease has progressed to the encephalitic stage, a combi-
nation of nifurtimox and eﬂornithine is the ﬁrst-line treatment
for T.b. gambiense infections while only the trivalent arsenical
melarsoprol can be used for stage 2 T.b. rhodesiense disease.4
All of these regimens rely on parenteral administration of the
drugs involved. Recently an orally deliverable drug, fex-
inidazole, has been trialed with some success in the treatment
of stage 1 and stage 2 of T.b. gambiense infections and may
replace the currently recommended treatment protocols for
this disease variant.24 Details of these chemotherapy regimens
have been fully described elsewhere.4,5,24
Neuropathogenesis
Postmortem examination
There are limited historical reports describing the neuropath-
ologic changes seen in patients after fatal T.b. gambiense and
T.b. rhodesiense infections. The earliest of these reports, made
by Mott1 in 1899, describes the neuropathologic changes in 2
fatal cases of “Negro Lethargy”. This study was performed prior
to trypanosomes being identiﬁed as the etiological agents of
“sleeping sickness;” however, the clinical and neuropathologic
signs described in the 2 Congolese patients clearly implicate
T.b. gambiense infection. In both cases, Mott describes the de-
velopment of a diﬀuse meningoencephalomyelitis with-
lymphocytes inﬁltrating along the blood vessels and into the
substance of the brain. This neuroinﬂammatory reaction is now
a recognized characteristic of CNS-stage HAT and has since
been noted in additional descriptions produced from fatal
cases.2,25–29 The inﬂammatory cell inﬁltrate is comprised pre-
dominantly of mononuclear lymphocytes together with a large
number of plasma cells.2,27,29 Morular or Mott cells are also
a common feature but cannot be considered as pathognomonic
of HAT.2,27,28 Marked astrocyte activation and microglial re-
activity accompanies the inﬂammatory cell inﬁltration and is
especially prominent in the white matter.28 Even in cases where
the neuroinﬂammatory reaction is severe, there appears to be
a signiﬁcant sparing of the nervous tissue and demyelination is
generally minimal.27–29 Indications of inﬂammation in the
ventricles and choroid plexus were noted on only a few occa-
sions by Mott2 and Adams;27 however in Calwell’s in-
vestigation of T.b. rhodesiense infections, lymphocyte
inﬁltration, ﬁbrosis, and edema were observed in the choroid
plexus in 7 of the 8 cases examined, although these patients had
received various trypanocidal drugs.28 In summary, the pre-
dominant neuropathologic changes associated with CNS-stage
HAT are most apparent in the white matter regions. These
changes are characterized by the presence of a diﬀuse,
lymphocytic-plasmacytic meningoencephalitis of varying se-
verity accompanied by activation of astrocytes and microglia;
however, only slight demyelination occurs and there is limited
neuronal involvement.
In some instances, patients experience a severe adverse reaction
to treatment with trypanocidal drugs, melarsoprol in particular,
resulting in the development of a posttreatment reactive en-
cephalopathy (PTRE).27 The neuropathologic lesions exhibi-
ted by these patients present as a signiﬁcant exacerbation of the
neuroinﬂammatory reaction described above with severe per-
ivascular cuﬃng and inﬂammatory cell inﬁltration of the brain
parenchyma. This reaction can progress in severity and features
associated with tentorial herniation and acute hemorrhagic
leukoencephalopathy have been reported.27
Animal models
Reports describing the neuropathologic changes in human
patients are uncommon so most of our knowledge regarding
neuropathogenesis has been derived from rodent and primate
Table Potential biomarkers of CNS-stage trypanosome infections
Biomarker/panel Methodology Trypanosome species
CXCL13, CXCL10, IgM20 CSF—immunoassay T.b. rhodesiense
CXCL13, CXCL10, MMP-920 CSF—immunoassay T.b. rhodesiense
CXCL10, CXCL8, H-FABP17 CSF—ELISA and bead suspension array T.b. gambiense
Neopterin, 5-hydroxytryptophan21 CSF—metabolomics T.b. gambiense
Ornithine, aminododecanoic acid21 Plasma—metabolomics T.b. gambiense
Neopterin18 CSF—ELISA T.b. gambiense
ICAM-1, MMP-916 CSF—bead suspension array T.b. gambiense
Osteopontin, β-2-microglobulin19 CSF—ELISA T.b. gambiense
CXCL10, lipocalin 2, SLPI15 CSF—ELISA T.b. gambiense, T.b. rhodesiense
Abbreviations: H-FABP =heart-fatty acid binding protein; ICAM= intercellular adhesionmolecule;MMP=matrixmetalloproteinase; SLPI = secretory leukocyte
peptidase inhibitor.
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models of the infection.30–34 The neuropathologic response
generated in these animal models is largely similar to the pat-
tern described in fatal cases of HATwith the most pronounced
reaction seen in the white matter and characterized by glial cell
activation accompanied by lymphocyte, macrophage, and
plasma cell invasion of the perivascular space and spreading to
the brain parenchyma in advanced disease. The neuro-
inﬂammatory response generally remains mild with severe
neuroinﬂammation and encephalitis most commonly reported
after subcurative drug treatment.33 This ﬁnding emphasizes the
relationship between exacerbation of the neuroinﬂammatory
reaction and trypanocidal drug administration and is most akin
to the situation encountered when patients develop the PTRE.
Themechanisms precipitating the PTRE remain unclear.Many
theories have been suggested including drug toxicity, the re-
lease of parasite antigens within the CNS, immune complex
deposition, autoimmunity, and a robust immune response to
residual parasites within the CNS after drug treatment.35 There
is some variation in the neuropathogenesis of the disease be-
tween species. Inﬂammatory lesions and trypanosomes are
commonly found in the choroid plexus in dogs with little in-
ﬁltration of the meninges. In contrast, the most severe response
is seen in the meninges in cattle with a less pronounced and
more focal reaction present in the choroid plexus.36
By combining animal models of HAT with contemporary
techniques such as confocal and multiphoton microscopy and
MRI details of the mechanisms generating the neuro-
inﬂammatory reaction and facilitating trypanosome trans-
migration into the CNS are beginning to emerge. However to
enter the brain parenchyma, inﬂammatory cells and parasites
must ﬁrst negotiate the blood-CNS barriers.
Blood-CNS barriers
Since optimal brain function is highly reliant on maintaining
a speciﬁc microenvironment, all inﬂux and eﬄux between the
central compartment and the periphery are tightly controlled.
Therefore, the CNS is eﬀectively isolated from the peripheral
systems by the presence of specialized barriers, situated at 3
main sites within the CNS, which regulate the passage of cells
andmolecules between the nervous tissue and the blood. There
are several diﬀerent pathways through these barriers that can be
utilized to access the brain and these are described in detail
elsewhere.37 The 3 barrier forms include the classical paren-
chymal blood-brain barrier (BBB), which separates the vascu-
lature from the CNS parenchyma; the blood-CSF barrier
(BCSFB), which forms an interface between the choroid plexus
and the ventricular CSF; and the arachnoid barrier, which is
found in the middle layer of the meninges and acts as a barrier
between the dura and the subarachnoid CSF. Morphologically,
diﬀerences exist between these barriers with the parenchymal
BBB showing the greatest complexity and being the most
prevalent of the 3 blood-CNS interfaces.37 The parenchymal
BBB is formed by several cell types including brain microvas-
cular endothelial cells that are joined by complex tight junctions
and pericytes, which partially surround the vessels and are
disseminated along the cerebral capillaries (ﬁgure). Both are
embedded in the endothelial basement membrane. This is
bordered by a CSF-ﬁlled perivascular space and further boun-
ded by the parenchymal basement membrane incorporating
the glial limitans perivascularis, comprised of astrocyte end-feet.
Neurons and microglial cells are found in close apposition to
these components (ﬁgure). These cell types interact to form
the neurovascular units that, together with the basement
membranes, constitute the parenchymal BBB.37 The function
of the blood-CNS barriers is dynamic, responding to a host of
signals originating in both the peripheral and the central
compartments, with barrier dysfunction having a major impact
in a wide range of disease etiologies.37
Transmigration of trypanosomes into the CNS
In vitro BBB models have been developed comprising cultured
human brain microvascular endothelial cells (HBMECs)
grown on Transwell inserts producing an upper and lower
compartment mirroring the luminal and abluminal sides of the
brain microvasculature. The HBMECs express a range of
markers and exhibit characteristics associated with BBB en-
dothelial cells in vivo.38 When trypanosomes are introduced
into the luminal side of the model, they transmigrate across the
HBMEC layer producing only a transient reduction in trans-
endothelial electrical resistance (TEER) suggesting that try-
panosome transmigration does not trigger an irreversible loss
of barrier function.38 Inhibition of several enzymes including
phospholipase C, protein kinase, and the parasite cysteine
protease brucipain (i.e., cathepsin-L) or chelation of Ca2+
prevents trypanosome transmigration and precludes the con-
comitant reduction in TEER.39 In addition, blocking the G
protein-coupled receptor, protease-activated receptor-2, shown
to trigger calcium-mediated transmembrane signaling in en-
dothelial cells, and previously implicated in a variety of neu-
roinﬂammatory conditions, can prevent parasite transmigration
across the in vitro barrier.40 These ﬁndings not only show that
parasites have the ability to traverse the BBB endothelial cell
layer but also suggest that calcium signaling could play an
important role in trypanosome invasion of the CNS (ﬁgure).
Despite these in vitro ﬁndings, microscopic examinations of
brain sections prepared from fatal HAT cases have detected
trypanosomes infrequently within the CNS. In a study of 6
postmortem cases of T.b. rhodesiense infection, Manuelidis
et al.29 found only a single parasite in the numerous sections
examined while Calwell28 failed to detect trypanosomes in the
CNS in a series of 17 patients. Mott2 also failed to detect intact
parasites in the brain tissue in T.b. gambiense patients, but
reported trypanosomes either conﬁned to blood vessels or the
presence of possible degenerate forms in the perivascular
inﬁltrates. Several hypotheses have been mooted to explain the
apparent absence of trypanosomes from the brain tissue in-
cluding the rapid degradation of parasites after death of the host
or clearance as a result of trypanocidal chemotherapy.27,28
In contrast, trypanosomes are frequently seen within the brain
parenchyma in rodent models during both acute41,42 and
chronic31,32,43,44 infections and have therefore facilitated the
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investigation of trypanosome invasion of the CNS. The
established paradigm suggests that the parasites use a mul-
tistepped process to colonize the brain parenchyma. In the
ﬁrst instance, trypanosomes appear in the stroma of the
choroid plexus and the circumventricular organs. In both of
these areas, the blood vessels are fenestrated, which could
allow passage of the parasites to the abluminal side. How-
ever, it is unlikely that these fenestrations alone provide
a suitable channel for trypanosome traversal because of their
restrictive size and a much more complex interplay between
the parasites and the epithelial cells is probable to facilitate
transmigration. Furthermore, to pass from the stroma of the
choroid plexus into the ventricular CSF, the trypanosomes
must deal with the BCSFB, formed by the choroid plexus
epithelial cells.45,46 The ability of trypanosomes to survive
within the choroid plexus and the CSF remains equivocal47
and the cyclical nature of the parasite burden in these areas
closely follows ﬂuctuations in parasitemia, which has been
suggested as a replenishing source of the trypanosome
population within these compartments.48 Additional studies
utilizing freeze fracture electron microscopy have proposed
that parasites persist as a viable population residing between
the cell layers of the pia mater thereby avoiding the appar-
ently hostile environs of the CSF.47
The eﬀects of trypanosome infection on blood-CNS barrier
function have been investigated using in vivo disease models.
Initial studies suggested that trypanosome infection reduced
barrier function during the later stages of the disease as
peripherally injected dye could be detected within the brain
parenchyma.44 These ﬁndings remained equivocal as no
changes in the presence of occludin and zonula occludens-1
or leakage of ﬁbrinogen and IgG into the brain could be
detected in a similar disease model.43 However, a more re-
cent study utilizing contrast-enhanced MRI in conjunction
with a murine HAT model has described a gradual and
progressive deterioration in barrier integrity beginning prior
to the onset of CNS-stage infection.30 Whether this is a di-
rect eﬀect of the trypanosomes or a symptom of the pe-
ripheral inﬂammatory reaction remains to be explained.
Further evidence suggests that this reduction in barrier
function is reversible and can be restored after curative
chemotherapy.49
Although it would seem logical to assume that the parasites
follow a step-wise dissemination from the CSF to the brain
parenchyma, studies by Masocha et al.50 suggest that the try-
panosomes gain entry to the neuropil via a hematogenous route
rather than originating from the CSF compartments. In fact,
Figure Purported mechanisms in the neuropathogenesis of HAT
In the healthy individual, a limited number of
T cells enter the brain to carry out immune
surveillance. AsHAT advances, lymphocytes and
parasites migrate from postcapillary venules
across the BBB to enter the brain parenchyma.
The mechanisms facilitating this progression
and those controlling the ensuing neuro-
inflammatory reaction are not fully understood;
however, some aspects have been elucidated.
The production of the cysteine protease, bruci-
pain, by the parasites increases their ability to
migrate across the BBB endothelial cell layer.
After activation in the peripheral compartment,
T-cell diapedesis through the endothelial cell
layer of the barrier can occur using both para-
cellular and transcellular routes. On breaching
the endothelial cell layer, both T-cells and try-
panosomes must penetrate the endothelial
basement membrane. This is dependent on the
laminin subtypes present. Areas where α4 lam-
inin predominates allow transmigration while
α5 laminin-rich regions inhibit crossing into the
perivascular space. Before reaching the brain
parenchyma, T cells and parasitesmust traverse
the parenchymal basement membrane. This
step appears to be dependent on a number of
factors including the presence of IFN-γ and the
production of MMPs, most likely by perivascular
macrophages, which disengage the astrocyte
end-feet from the glial limitans allowing the cells
to enter the brain. The T cells can then interact
with residentmicroglia, astrocytes, or additional
lymphocytes that can each produce a range of
inflammatory mediators. The overall balance of
these mediators is critical in controlling the
neuroinflammatory response and BBB integrity
and may prompt clinical manifestations of the
disease including pyrexia, cachexia, and sleep
disturbances. BBB = blood-brain barrier; HAT =
human African trypanosomiasis; MMP = matrix
metalloproteinases.
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using confocal microscopy, T. b. brucei has been detected
throughout the cortex, septum, corpus callosum, striatum,
thalamus, and traversing blood vessels in the hypothalamus at
9-day postinfection using double immunoﬂuorescence to label
both trypanosomes and brain microvascular endothelial cells in
a rat model of HAT.42 This early CNS invasion has also been
demonstrated by intravital microscopy to reveal both T. b.
brucei and T.b. rhodesiense parasites, genetically modiﬁed to
express a ﬂuorescent marker, within the parietal cortex 5 hours
after high-dose IV infections in C57Bl/6 mice.41 However, the
relevance of these ﬁndings of early and widespread CNS in-
vasion to the situation found in HAT remains equivocal. It is
therefore clear that further work is warranted to establish more
accurate temporal-spatial kinetics to comprehend exactly when
and where trypanosomes enter the CNS.
Influence of immune factors
The mechanisms employed by the parasites to circumvent the
CNS barriers and generation of the associated neuro-
inﬂammation are multifactorial and not fully understood.
However, evidence is emerging to suggest that the innate im-
mune response plays an important role in HATpathogenesis.51
Mice deﬁcient in Toll-like receptor (TLR)-9, an innate sig-
naling molecule, exhibit lower numbers of T cells in the CNS
compared to their wild-type counterparts after trypanosome
infection.52 MyD88 is an intracellular adaptor protein required
for maintaining the downstream TLR signal transduction
pathways responsible for generating innate inﬂammation as
well as priming the adaptive immune response. Reduced
numbers of T cells were found in the brain in infected MyD88
knockout mice, accompanied by a corresponding increase in
parasite numbers that were not present in TLR-9 knockout
mice. Therefore, taken together these ﬁndings suggest that
pathways other than TLR-9, involving MyD88 signaling, may
play a role in controlling the trypanosome population within
the brain.52 However, ablation of IL-1R, IL-18, TLR-2, or TLR-
4, which all signal through MyD88, did not show alterations in
T cell or parasite levels in the brain.52 TLR signaling is closely
involved with the control of cytokine and chemokine expres-
sion and these important immunologic moderators are known
to play key roles in the progression of trypanosome infec-
tions.51 In summary, TLR signaling has been shown to stim-
ulate the expression of TNF-α and type-1 IFN that could
initiate a cascade of events culminating in trypanosome and
T-cell transmigration into the CNS while additional mediators
within the brain exert control over the expansion of the parasite
population residing within the CNS.
Another pathway recently implicated in the generation of the
neuroinﬂammatory reaction to trypanosome infection is
the kynurenine pathway.53,54 This pathway is fundamental in
the oxidation of tryptophan, produces several neurotoxic and
neuroprotective catabolites, and is important in inﬂuencing
both the innate and adaptive immune response.55 In a murine
model of HAT, inhibition of kynurenine 3-monooxygenase,
a key enzyme in this pathway, resulted in a signiﬁcant reduction
in the severity of the neuroinﬂammatory reaction exhibited
during the late CNS stage of the infection.54 Activation of this
pathway has been found through liquid chromatography-mass
spectrometry analysis of CSF samples from patients with both
early and late-stage HAT.53 In these patients, signiﬁcant
increases in kynurenine levels, accompanied by decreased
tryptophan concentrations, were observed in infected individ-
uals compared to uninfected controls.53 An associationwas also
found between tryptophan catabolism and increased CSF IL-6
concentrations, providing further evidence to support a role for
this pathway in the neuropathogenesis of HAT. Changes in the
concentration of kynurenine pathway metabolites in the CSF
were also identiﬁed in ametabolomics study, designed to detect
potential biomarkers for late-stage HAT, although these
changes were small.21
In a murine model of HAT, several cytokines, including TNF-
α and IFN-γ, have been associated with the presence of
a moderate to severe neuroinﬂammatory reaction, while IL-10
and IL-6 were found at higher levels early after infection when
only a mild neuroinﬂammation was present.56 The impor-
tance of these cytokines in CNS-stage infections was further
demonstrated through ﬁnding that T cells and trypanosomes
arrest in the perivascular space and do not progress through
the parenchymal basement membrane to enter the neuropil in
IFN-γ or IFN-γ receptor knockout mice (ﬁgure). This phe-
nomenon was also seen in IL12p40 knockout mice that
cannot initiate IFN-γ secretion.50 Furthermore, systemic ad-
ministration of IL-10 in a late-stage mouse model of HAT
improved the clinical response of the animals to the infection
compare to untreated animals.57 IL-10 treatment also resulted
in lower plasma levels of IFN-γ and TNF-α, accompanied by
a reduction in the severity of the neuroinﬂammatory reaction
and parasite burden in the brain, which may be a consequence
of the reduced presence of IFN-γ.57
The close association between T-cell and parasite trans-
migration into the CNS after trypanosome infection has been
further demonstrated. In a similar pattern to T-cell trans-
migration, vascular basement membrane regions expressing
laminin α4 were shown to be permissive to parasites while
areas where laminin α5 predominated inhibited parasite
crossing.50 In the CNS, laminin α4 regions are widespread
along the endothelial basement membrane whereas laminin
α5 areas occur less frequently. However, to facilitate passage
into the neuropil, the cells and parasites must also traverse
the parenchymal basement membrane (ﬁgure). Activation of
matrix metalloproteinases (MMPs)-2 and -9 cleave the
dystroglycan receptors from the astrocyte end-feet causing
them to disengage from the parenchymal basement mem-
brane, compromising the integrity and allowing trans-
migration into the brain.58 Increased MMP activity, together
with decreased activation of tissue inhibitors of MMPs at the
BCSFB in vitro, has been associated with TNF-α expression,
leading to increased barrier permeability,59 again implicating
a pivotal role for this molecule in the progression of HAT.
Furthermore, critical roles for both laminins and MMPs, and
their integral connection with cytokine and chemokine
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expression, have been identiﬁed in the progression of ex-
perimental autoimmune encephalomyelitis,45 and changes
in the expression pattern of MMPs have been detected in
rodent models of HAT.60
Discussion
Although many advances have been made with regard to
understanding the pathogenesis of HAT, there are still nu-
merous unanswered questions and areas where our current
knowledge remains incomplete. A fuller understanding of
the pathways involved in the disease process will provide
insights to improve management strategies and chemo-
therapy options. Therefore, the continued application of
contemporary analytics, combined with both in vivo and in
vitro approaches to model the disease, together with im-
proved access to human samples is necessary to achieve
a greater understanding of this ancient and complex parasitic
infection.
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